Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

被引：0
作者：
Ryan Thaliffdeen
Anthony Yu
Karen Rascati
机构：
[1] The University of Texas at Austin,Health Outcomes Division, College of Pharmacy
来源：
Clinical Drug Investigation | 2024年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：209 / 217
页数：8
相关论文
共 50 条
[21]   COST EFFECTIVENESS MODEL ON FOUR PREVENTIVE TREATMENT FOR CLOSTRIDIOIDES DIFFICILE INFECTION RECURRENCE FROM A US PAYER PERSPECTIVE [J].
Gomez-Lumbreras, A. ;
Schmutz, H. ;
Tawfik, A. G. ;
Malone, D. C. .
VALUE IN HEALTH, 2024, 27 (06) :S57-S57
[22]   Efficacy, Safety, and Tolerability of Rimegepant 75 Mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-blind, Randomized, Placebo-controlled Trial, Study 302 [J].
Lipton, R. B. ;
Coric, V ;
Stock, E. G. ;
Stock, D. ;
Morris, B. A. ;
McCormack, T. ;
Frost, M. ;
Gentile, K. ;
Conway, C. M. ;
Croop, R. .
HEADACHE, 2018, 58 (08) :1289-1289
[23]   COST-EFFECTIVENESS AND LONG-TERM OUTCOMES OF SOVALDI (SOFOSBUVIR) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (HCV) PATIENTS FROM A SWEDISH SOCIETAL PERSPECTIVE [J].
Cure, S. ;
Guerra, I .
VALUE IN HEALTH, 2014, 17 (07) :A675-A675
[24]   Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors (vol 4, e2129392, 2021) [J].
Ito, K. ;
Chapman, R. ;
Pearson, S. D. ;
Tafazzoli, A. ;
Yaffe, K. ;
Gurwitz, J. H. .
JAMA NETWORK OPEN, 2024, 7 (08)
[25]   COST-EFFECTIVENESS ANALYSIS OF ELADOCAGENE EXUPARVOVEC FOR THE TREATMENT OF AROMATIC LAMINO ACID DECARBOXYLASE DEFICIENCY (AADCD) FROM A UNITED STATES (US) PERSPECTIVE [J].
Monteleone, B. ;
Zhang, R. ;
Castellano, P. ;
Oconnell, T. ;
Teng, Y. ;
Tomazos, I .
VALUE IN HEALTH, 2024, 27 (12)
[26]   BUDGET-IMPACT AND COST-EFFECTIVENESS OF TILDRAKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM A US HEALTH PLAN PERSPECTIVE [J].
Carrico, J. ;
Jia, X. ;
Zhao, Y. ;
Zhang, J. ;
Brodtkorb, T. H. ;
Mendelsohn, A. B. ;
Lowry, S. ;
Wu, J. J. ;
Feldman, S. R. ;
Armstrong, A. W. .
VALUE IN HEALTH, 2019, 22 :S52-S52
[27]   DECISION ANALYSIS MODEL EVALUATING THE COST-EFFECTIVENESS OF FIDAXOMICIN AND VANCOMYCIN IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) FROM A HOSPITAL PERSPECTIVE [J].
Alowayesh, M. S. ;
Holdford, D. ;
Harpe, S. E. .
VALUE IN HEALTH, 2012, 15 (04) :A243-A243
[28]   Evaluation of the cost-effectiveness of concomitant oral and topical mesalazine treatment versus oral treatment alone in mild-to-moderate active ulcerative colitis: A decision-analytic model [J].
Nielsen, S. K. ;
Connolly, M. P. ;
Bhatt, A. ;
Currie, C. J. .
VALUE IN HEALTH, 2007, 10 (06) :A353-A353
[29]   Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women:: Results of a Markov model from the public sector perspective [J].
Gutierrez-Delgado, Cristina ;
Baez-Mendoza, Camilo ;
Gonzalez-Pier, Eduardo ;
Prieto de la Rosa, Alejandro ;
Witlen, Renee .
SALUD PUBLICA DE MEXICO, 2008, 50 (02) :107-118
[30]   The cost-effectiveness of pioglitazone compared with sitagliptin: An economic evaluation using a validated economic model from a third party payer perspective in the USA [J].
Minshall, M. ;
St. Charles, M. ;
Pandya, B. ;
Baran, R. W. ;
Bron, M. .
VALUE IN HEALTH, 2007, 10 (06) :A259-A259
12345